Twice-yearly HIV prevention drug lenacapavir gains FDA approval and WHO recommendation after 100% efficacy in trial
Lenacapavir, a twice-yearly injectable HIV prevention drug, demonstrated 100% efficacy in a 2024 clinical trial of over 2,000 young women in South Africa and Uganda. The drug is now approved by the US FDA and recommended by the WHO for global HIV prevention. Widespread access in low- and middle-income countries is delayed until 2027 due to patent and pricing issues.
Why it matters
This addresses the difficulty of adhering to daily HIV prevention regimens by providing a twice-yearly injection that has cleared key regulatory and global health hurdles.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news